Esperion Therapeutics (ESPR) Tops Q4 EPS by 9c

Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($0.76), $0.09 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $18.18 million versus the consensus estimate of $20.57 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Dollar stores see mixed outlook ahead of earnings next week, Gordon Haskett comments
• Lowe's (LOW) PT Lowered to $275 at Guggenheim